Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

• Status: Recruiting
• Trial end date: 2022-07-30

Summary

This phase I/II trial studies the best dose of sorafenib when given together with busulfan and fludarabine in treating patients with acute myeloid leukemia that has come back or does not respond to treatment and who are undergoing donor stem cell transplant. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as busulfan and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving sorafenib with busulfan and fludarabine may work better in treating patients with recurrent or refractory acute myeloid leukemia.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborators: Bayer; National Cancer Institute (NCI)
• Treatments: Busulfan; Cyclophosphamide; Fludarabine; Fludarabine phosphate; Lenograstim; Mycophenolic Acid; Niacinamide; Sargramostim; Sorafenib; Tacrolimus; Vidarabine